Li Wanjun, chairman of Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd., Jiang Pan, deputy general manager, and Wei Pingzhi, project manager, visited Chutian Huatong on August 6th and served as the R&D center of Chutian Huatong Zhifeilongkoma Industrial Park The executive team of the project and the New Crown Vaccine Project awarded Chutian Huatong the honorary titles of "Excellent Technical Team" and "Excellent Supplier", and awarded Chutian Huatong employees Jiang Haiyang and Cai Fuqiang "Excellent Project Manager" and "Excellent Construction Manager" "Honorary title," at the same time as a gift to Chutian Huatong Chairman Yang Wenlu and employees Jiang Haiyang and Cai Fuqiang "Zhifei Biological 100 million doses" commemorative silver coins.

Shandong New Times Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, held the first high-level forum for high-quality equipment suppliers in Linyi City, Shandong Province on July 20. Chutian Technology has made a leap in the course of cooperation with Lunan Pharmaceutical Group. Zeng Fanyun, a strategic partner for nearly 20 years, was invited to participate in the forum and accepted the honor of "Quality Supplier" awarded by New Era Pharmaceutical on behalf of the company.

Shandong New Times Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, held the first high-level forum for high-quality equipment suppliers in Linyi City, Shandong Province on July 20. Chutian Technology has made a leap in the course of cooperation with Lunan Pharmaceutical Group. Zeng Fanyun, a strategic partner for nearly 20 years, was invited to participate in the forum and accepted the honor of "Quality Supplier" awarded by New Era Pharmaceutical on behalf of the company.

Shandong New Times Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, held the first high-level forum for high-quality equipment suppliers in Linyi City, Shandong Province on July 20. Chutian Technology has made a leap in the course of cooperation with Lunan Pharmaceutical Group. Zeng Fanyun, a strategic partner for nearly 20 years, was invited to participate in the forum and accepted the honor of "Quality Supplier" awarded by New Era Pharmaceutical on behalf of the company.

Chutian Technology's 2021 semi-annual report was released on August 27. Many indicators such as revenue and net profit have risen sharply. In the first half of the year, operating income was 2.391 billion yuan, a year-on-year increase of 72.75%; net profit attributable to shareholders of listed companies was 236 million Yuan, a year-on-year increase of 1321.22%. Among the many product sectors that support business performance, inspection and packaging solutions and stand-alone business are very eye-catching, with revenue reaching 830 million yuan, an increase of 135.42% year-on-year, while the bioengineering solutions and stand-alone business sectors are developing rapidly, with revenue increasing year-on-year 255.41%. R&D investment continued to rise steadily, reaching nearly 200 million yuan, a year-on-year increase of 65.65%. Although overseas markets are affected by the uncertainty of the new crown epidemic, Chutian Technology has also performed well in several overseas regions in the first half of 2021. For example, revenue in Europe increased by 11.27% and revenue in America increased by 74.67%.

楚天科技2021年半年度报告8月27日发布，营收、净利润等多项指标均大幅上扬，上半年营业收入23.91亿元，同比增长72.75%；归属于上市公司股东的净利润2.36亿元，同比增长1321.22%。在支撑起经营业绩的众多产品板块中，检测包装解决方案及单机业务十分亮眼，营收达到8.3亿元，同比增长135.42%，生物工程解决方案及单机业务板块则发展迅猛，营收同比增长255.41%。研发投入继续稳步抬升，近2亿元，同比增长65.65%。海外市场虽然受到新冠疫情的不确定性影响，但楚天科技2021年上半年在若干海外地区也有不错表现，比如欧洲地区营收同增11.27%、美洲地区营收同增74.67%。